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Abstract
Background: Existing evidence for validity of the visual analog scale of the EQ-5D-3L questionnaire (EQ-VAS) is
weak in Chinese-speaking respondents in Singapore. We therefore investigated the validity of the Chinese
(Singapore) version of EQ-VAS in patients with diabetes.
Methods: In a cross-sectional survey, patients with type 2 diabetes seen in a primary care facility completed an
identical Chinese or English questionnaire containing the EQ-5D-3L and questions assessing other health and
disease-related characteristics. Convergent and known-groups validity of the EQ-VAS was examined for Chinese-
and English-speaking respondents separately.
Results: The EQ-VAS was correlated with the EQ-5D-3L health index and a 5-point Likert-type scale for assessing
global health in both Chinese-speaking (N = 335) and English-speaking respondents (N = 298), suggesting
convergent validity. The mean EQ-VAS scores differed between English-speaking patients with differing duration of
diabetes (< 10 years versus ≥ 10 years), comorbidity status (absence versus presence), and complications of
diabetes (absence versus presence), providing evidence for known-groups validity. However, the EQ-VAS scores for
Chinese-speaking respondents known to differ in these characteristics were similar, even among subgroups of
relatively younger patients or those with formal school education.
Conclusions: Chinese- and English-speaking Singaporeans respond differently to the EQ-VAS. The Chinese version of
EQ-VAS appears less sensitive than its English version for measuring global health in patient populations in Singapore.
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Introduction
The visual analog scale (VAS) in the EQ-5D-3L self-report
questionnaire [1] is a single-item measure of global health
that has demonstrated satisfactory psychometric proper-
ties in many populations [2-5]. However, the Chinese ver-
sion of the EQ-VAS exhibited weak construct validity in
Singapore, a multi-ethnic urban country in South-East
Asia. In two previous studies in Singapore [6,7], expected
associations between the EQ-VAS and other health or
clinical measures were not observed among patients with
rheumatic or Parkinson’ disease who completed the Chi-
nese EQ-5D-3L questionnaire; in contrast, the English
version of the EQ-VAS showed good construct validity in
the same studies [7,8]. Hence, validity of the EQ-VAS
among Chinese-speaking Singaporeans warrants further
investigation.
T h ep u r p o s eo ft h ep r e s e n ts t u d yw a st oi n v e s t i g a t e
the construct validity of the EQ-VAS in Chinese-speak-
ing patients with type 2 diabetes using data collected in
a health survey of such patients in Singapore. Perfor-
mance of the English version of the EQ-VAS was also
assessed and served as a reference in this study.
Methods
Patients and procedures
Outpatients with type 2 diabetes visiting one of the 8
SingHealth Polyclinics over the period of the 6
th to 12
th
January 2009 were recruited for this study using a
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of 21 years or older, a diagnosis of type 2 diabetes melli-
tus, and ability to communicate and give informed
consent.
All patients going for HbA1c test were assessed for elig-
ibility by trained year-3 medical students. Consenting
patients were asked to complete a survey form in the wait-
ing area of the clinics containing the EQ-5D-3L question-
naire, a question for self-assessment of global health, and
questions assessing demographic, clinical, and health char-
acteristics. Identical English and Chinese questionnaires
were prepared for patients to choose at their own prefer-
ence. Patients could choose to complete the questionnaire
by themselves or through an interviewer.
Outcome measures
The EQ-5D-3L questionnaire has two pages. Page one is
for respondents to report whether they have no, moderate,
or extreme problems in mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression on the day of sur-
vey. An index score ranging from -0.594 to 1.0 (0 = dead;
1.0 = full health) can be calculated from the answers to
represent the value of a respondent’s health status [9]. The
second page is the EQ-VAS for respondents to assess their
‘own health state today’. It is a hash-marked, vertical VAS
numbered with 0, 10, 20, 30,..., 80, 90, 100 from bottom
(0) to top (100). The labels of ‘worst/best imaginable
health state’ are attached to the bottom and top of the
scale, respectively.
The question for self-assessment of global health was
phrased as ‘In general, how would you say your health is?’
The response options were ‘excellent’, ‘very good’, ‘good’,
‘fair’,a n d‘poor’.
Data analysis
Convergent validity of the EQ-VAS was assessed accord-
ing to its correlation with the EQ-5D-3L index and self-
assessment of global health. Known-groups validity was
evaluated by comparing subgroups of patients known to
differ in health status [10]. We hypothesized that the EQ-
VAS score would be lower in patients known to have
‘worse’ health than those had ‘better’ health. The known
groups were defined according to body mass index (non-
obese versus obese), duration of diabetes (< 10 years ver-
sus 10 or more years), diabetes-related complications
(absence versus presence), and comorbid chronic condi-
tions (absence versus presence). Data collected from Chi-
nese and English questionnaires were analyzed separately
to assess the validity of both versions of the EQ-VAS.
Additionally, in order to examine the possible effects of
age and education on the known-groups validity of the
Chinese VAS, we assessed the above-mentioned known
groups for younger (defined as age < 70 years) and older
(defined as age ≥ 70 years) patients separately and for
patients with no formal education and those with formal
education separately. We hypothesized that the EQ-VAS
would be more discriminative among patients of younger
age and those with formal education.
Differences in EQ-VAS scores between known-groups
were quantified using linear regression models. Socio-
demographic characteristics such as age, gender, ethni-
city, employment status, education, and survey mode
(interviewer-administration versus self-completion),
whenever appropriate, were included into the models as
independent variables to adjust for their effects on the
EQ-VAS score. All statistical tests were two-sided and
performed with SAS for Windows (Version 9.2, SAS
Institute INC., Cary NC, USA).
Results
A total of 335 and 298 participants completed the survey
in Chinese and English, respectively. Demographic and
health characteristics of the study sample are displayed in
Table 1. Compared to participants who completed the
survey in Chinese, participants completing the survey in
English were younger, better educated, and more likely to
be females and employed. Accordingly, more Chinese-
than English-speaking patients reported one or more
comorbidities (80.9% versus 70.8%, p = 0.003) and rated
their health as ‘fair’ or ‘poor’ (38.8% versus 27.6%, p =
0.003). The majority of patients chose to complete the
survey through an interviewer, although a larger propor-
tion of English-speaking patients than Chinese-speaking
patients completed the survey by themselves (29.2%
versus 5.1%, p < 0.001).
For Chinese-speaking patients, the EQ-VAS was corre-
lated with the EQ-5D-3L index (Spearman’s correlation
coefficient: 0.27) and self-assessed global health (Spear-
man’s correlation coefficient: -0.51), suggesting conver-
gent validity. However, there was no statistical difference
in EQ-VAS scores between subgroups of patients known
to differ in BMI, duration of diabetes, complication sta-
tus, or comorbidity status in both univariate and multi-
variate analysis, suggesting poor known-groups validity
(Table 2). For example, the multiple regression analysis
s h o w e dt h a tt h ed i f f e r e n c ei nE Q - V A Ss c o r eb e t w e e n
patients with and without any comorbidity was 1.7 (p >
0.05, t-test) after adjusting for socio-demographic status.
Subgroup analyses suggested that known-groups validity
was not better among patients with formal education
than those without formal education (Table 3), or among
younger patients than older patients (Table 4).
In contrast, the EQ-VAS demonstrated both convergent
and known-groups validity among patients who elected to
complete the survey in English. Spearman’s correlation
coefficient was 0.31 between the EQ-VAS and EQ-5D-3L
index and -0.56 between the EQ-VAS and self-assessed
global health. Patients with 1 or more diabetes-related
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than those without such conditions, and patients who had
diabetes for < 10 years had higher EQ-VAS scores than
those who had diabetes for 10 or more years. Those differ-
ences were statistically significant even after controlling
for the effect of socio-demographic status in the multiple
regression models (Table 2). It was also as hypothesized
that non-obese patients had higher EQ-VAS scores than
obese patients, although the difference was not statistically
significant. It should be noted that the magnitude of the
mean differences between the comparison groups was not
larger (range: 3.0 to 7.8)
Discussion
In the present study, the EQ-VAS exhibited poor known-
groups validity among Chinese-speaking patients with
diabetes, although convergent validity was demonstrated
by correlations between the EQ-VAS and two other mea-
sures of overall health. In contrast, both convergent and
known-groups validity were observed for the English EQ-
VAS. Similar results were also observed for the EQ-VAS
in patients with rheumatic diseases [6], Parkinson’sd i s -
ease [7], and breast cancer (Yin-Bun Cheung, personal
communication). Therefore, it appears that the Chinese
EQ-VAS is not a sensitive measure for self-assessment of
overall health in Singaporean patient populations. To the
best of our knowledge, no previous studies questioned
the sensitivity of the EQ-VAS in specific or the visual
analog scale in general.
Our finding from the present study has some important
implications. First, our study highlighted the importance
of psychometric testing for health-status instruments.
Table 1 Characteristics of Patients
Patients completing the Chinese
EQ-5D-3L (N = 335)
Patients completing the English
EQ-5D-3L (N = 298)
P value
Age at survey, mean(SD) 65.9 (9.0) 59.2 (10.8) < 0.001
Male, N (%) 144 (43.1) 157 (53.2) 0.011
Ethnicity, N (%)
Chinese 335 (100) 166 (56.1) < 0.001
Malay/India/other 0 (0) 130 (43.9)
Employment status, N (%)
Employed 99 (29.6) 140 (47.3) < 0.001
Retired 139 (41.5) 86 (29.1)
Housekeeper/unemployed 97 (28.9) 70 (23.6)
Education attainment, N (%)
No formal qualifications 134 (40.4) 31 (10.5) < 0.001
Primary school education 121 (36.4) 59 (20.1)
Secondary school education 61 (18.4) 117 (39.8)
Tertiary education 16 (4.8) 87 (29.6)
BMI category
Non-obese (BMI < 30), N (%) 280 (87.0) 233 (81.2) 0.122
Obese (BMI ≥ 30), N (%) 42 (13.0) 54 (18.8)
Duration of diabetes
< 10 years, N (%) 180 (45.9) 168 (56.9) 0.466
≥ 10 years, N (%) 153 (54.1) 127 (43.1)
Presence of 1 or more diabetes-related
complications, N (%)
144 (43.0) 112 (37.6) 0.167
Presence of 1 or more comorbidities, N (%) 271 (80.9) 211 (70.8) 0.003
Self-reported global heath
Excellent/very good/good 205 (61.2) 215 (72.4) 0.003
Fair/poor 130 (38.8) 82 (27.6)
EQ-VAS, mean (SD) 68.9 (16.7) 69.9 (16.8) 0.498
EQ-5D-3L index score, mean(SD) 0.86 (0.18) 0.87 (0.19) 0.519
Administration mode
Self-completion 17 (5.1) 87 (29.2) < 0.001
Interviewer-administered 318 (94.9) 211 (70.8)
Notes: complications were conditions or diseases related to diabetes including stroke, ischemic heart disease, kidney disease, peripheral neuropathy, peripheral
vascular disease, and eye disease; comorbidities included cancer, arthritis, hypertension, high blood cholesterol, asthma, lung conditions, liver conditions, mental
disorders, urological disease, and ear, nose or throat diseases.
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population may not necessarily be generalized to other
populations especially those multi-cultural populations.
This is true even for widely used simple instruments
such as the VAS. Herdman et al. pointed out that mea-
surement equivalence across language versions should be
examined in cross-cultural application of health-related
quality of life instruments [ 1 1 ] .S e c o n d ,o u rs t u d ys u g -
gested that the EQ-VAS is not a sensitive measure for
Chinese-speaking patients in Singapore. Although being
a valid measure, the EQ-VAS may not be able to detect
true differences between groups when such differences
are small. When a measure for overall health is needed
for this population, the EQ-5D-3L index may a better
choices as it demonstrated better known-groups validity
in the present study (see Table 5). Third, we can reason-
ably suspect that other variants of the VAS used in clini-
cal research or practice in Singapore may suffer from
similar problems when they are applied to Chinese-
speaking patients. Since no previous studies have looked
into the psychometric properties of other VAS variants
in Singapore, investigators should be cautious when
Table 2 Comparison of EQ-VAS Scores between Subgroups with Different Health Status: by Survey Language
Patients completing the Chinese
EQ-5D-3L
Patients completing the English
EQ-5D-3L
N Mean (SD) Adjusted difference*
(p-value)




< 30 280 69.0 (16.5) -1.4 233 70.7 (16.4) 3.0
≥ 30 42 70.7 (17.6) (0.612) 54 67.6 (16.4) (0.241)
Duration of DM
< 10 years 180 69.7 (17.7) 1.1 168 72.8 (15.1) 5.8
≥ 10 years 153 68.1 (15.1) (0.564) 127 66.8 (17.5) (0.003)
Presence of complications
No 188 70.7 (17.5) 3.6 184 73.4 (14.2) 7.8
Yes 144 67.0 (15.4) (0.057) 112 65.0 (18.3) (< 0.001)
Presence of comorbidities
No 61 68.4 (17.8) -1.7 85 75.6 (15.4) 6.8
Yes 271 69.2 (16.4) (0.493) 211 68.0 (16.3) (0.002)
Notes: complications were conditions or diseases related to diabetes including stroke, ischemic heart disease, kidney disease, peripheral neuropathy, peripheral
vascular disease, and eye disease; comorbidities included cancer, arthritis, hypertension, high blood cholesterol, asthma, lung conditions, liver conditions, mental
disorders, urological disease, and ear, nose or throat diseases. * values are regression coefficients in multiple linear regression models in which the effects of
administration mode, age, gender, employment status, and education using linear regression models are adjusted for.
Table 3 Comparison of EQ-VAS Scores between Subgroups with Different Health Status: by Education Level for
Patients Completing the Chinese EQ-5D-3L
No formal education (N = 134) With formal education (N = 198)
N Mean (SD) Adjusted difference*
(p-value)




< 30 109 69.5 (17.1) 1.4 170 68.8 (16.1) -4.1
≥ 30 18 66.9 (18.6) (0.754) 24 73.5 (16.7) (0.257)
Duration of DM
< 10 years 65 70.8 (18.0) 4.5 114 69.3 (17.1) -1.4
≥ 10 years 69 66.4 (16.3) (0.143) 84 69.5 (15.3) (0.579)
Presence of complication
No 74 69.4 (18.9) 1.9 114 71.5 (16.7) 4.0
Yes 60 67.6 (14.9) (0.538) 84 66.5 (15.3) (0.104)
Presence of comorbidities
No 21 63.3 (14.5) -6.0 40 71.0 (18.9) 0.9
Yes 113 69.5 (17.5) (0.166) 158 68.9 (15.6) (0.771)
Notes: complications were conditions or diseases related to diabetes including stroke, ischemic heart disease, kidney disease, peripheral neuropathy, peripheral
vascular disease, and eye disease; comorbidities included cancer, arthritis, hypertension, high blood cholesterol, asthma, lung conditions, liver conditions, mental
disorders, urological disease, and ear, nose or throat diseases. * values are regression coefficients in multiple linear regression models in which the effects of
administration mode, age, gender, employment status, and education using linear regression models are adjusted for.
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patients using such scales.
It is intriguing why the EQ-VAS performed differently
among Chinese- and English-speaking Singaporeans. We
thought older age and poor education might be the rea-
sons as those were the main differences between Chinese-
and English-speaking patients. We speculated that some
older patients or poorly educated patients might not know
how to use the EQ-VAS for self-rating because of age-
related cognitive impairment or poor numeracy, respec-
tive. However, our results did not support this hypothesis;
the insensitivity of EQ-VAS to different health status was
not associated with education or age (Tables 3 and 4).
Although determining the real reason for the observed
results is beyond the scope of the present study, the possi-
ble reasons should be related to different response styles
of the respondents. It may be that Chinese speakers in Sin-
gapore have some idiosyncratic response style such that
relatively healthy Chinese-speaking patients score their
own health lower than their English counterparts on the
VAS. Chinese philosophies such as Middle Way [12] may
make practitioners avoid using high or low VAS scores to
Table 4 Comparison of EQ-VAS Scores between Subgroups with Different Health Status: by Age Group for Patients
Completing the Chinese EQ-5D-3L
< 70 years (N = 211) 70 years or older (N = 124)
N Mean (SD) Adjusted difference*
(p-value)




< 30 173 70.2 (16.7) 0.0 107 67.1 (16.0) -5.1
≥ 30 32 70.8 (16.7) (0.997) 10 70.4 (21.3) (0.354)
Duration of DM
< 10 years 130 70.6 (17.6) 1.3 50 67.4 (17.0) 0.4
≥ 10 years 81 68.9 (15.3) (0.584) 72 67.2 (16.4) (0.897)
Presence of complication
No 137 71.3 (17.3) 3.3 51 69.0 (18.4) 1.7
Yes 73 67.8 (15.3) (0.185) 71 66.1 (15.1) (0.589)
Presence of comorbidities
No 47 68.0 (18.7) -3.4 14 69.6 (15.1) -0.2
Yes 163 70.7 (16.0) (0.239) 108 67.0 (16.8) (0.964)
Notes: complications were conditions or diseases related to diabetes including stroke, ischemic heart disease, kidney disease, peripheral neuropathy, peripheral
vascular disease, and eye disease; comorbidities included cancer, arthritis, hypertension, high blood cholesterol, asthma, lung conditions, liver conditions, mental
disorders, urological disease, and ear, nose or throat diseases. * values are regression coefficients in multiple linear regression models in which the effects of
administration mode, age, gender, employment status, and education using linear regression models are adjusted for.
Table 5 Comparison of EQ-5D-3L Index Scores between Subgroups with Different Health Status: by Survey Language
Patients completing the Chinese
EQ-5D-3L
Patients completing the English
EQ-5D-3L
N Mean (SD) Adjusted difference*
(p-value)




< 30 280 0.867 (0.174) 0.020 231 0.892 (0.161) 0.080
≥ 30 41 0.849 (0.207) (0.501) 54 0.799 (0.234) (0.003)
Duration of DM
< 10 years 179 0.882 (0.139) 0.034 168 0.897 (0.161) 0.043
≥ 10 years 153 0.836 0.209) (0.090) 125 0.843 (0.199) (0.039)
Presence of complications
No 187 0.897 (0.138) 0.073 183 0.917 (0.113) 0.102
Yes 144 0.814 (0.208) (< 0.001) 111 0.803 (0.239) (< 0.001)
Presence of comorbidities
No 60 0.889 (0.130) 0.011 85 0.926 (0.148) 0.056
Yes 271 0.855 (0.185) (0.685) 209 0.852 (0.187) (0.015)
Notes: complications were conditions or diseases related to diabetes including stroke, ischemic heart disease, kidney disease, peripheral neuropathy, peripheral
vascular disease, and eye disease; comorbidities included cancer, arthritis, hypertension, high blood cholesterol, asthma, lung conditions, liver conditions, mental
disorders, urological disease, and ear, nose or throat diseases. * values are regression coefficients in multiple linear regression models in which the effects of
administration mode, age, gender, employment status, and education using linear regression models are adjusted for.
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tant to say their health is very good because they are afraid
that God may punish them for not being humble [13].
However, we cannot rule out the possibility that the poor
performance of the Chinese EQ-VAS was due to the sub-
optimal translation of the instructions and anchor labels
of the instrument. Future studies using qualitative research
methods such as focus group discussion should be con-
ducted to elicit the causes for the poor sensitivity to differ-
ence of the Chinese version of the EQ-VAS.
There were some limitations in our study. First, all
data used in our study were self-reported data. Chinese-
speaking patients might have reported less accurate
information on complication or comorbidity profiles
than English-speaking patients because they were older.
If this was the case, the known-groups validity of the
Chinese EQ-VAS would have been underestimated in
this study. Second, the internal validity of our results
might have been affected by respondents’ self-selection
of survey languages. It is possible that those bilingual
respondents who choose the Chinese questionnaires
happened to have different response style. Ideally, bilin-
gual respondents were identified and randomized to
complete the survey in English or Chinese. Third, the
finding of our study only has limited external validity.
Since our finding is purely based on patients with dia-
betes, it may not be generalized to all patient popula-
tions in Singapore. Nevertheless, similar results were
also observed for rheumatic diseases, Parkinson’sd i s -
ease, and breast cancer. Additionally, our study may not
be generalized to other Chinese-speaking populations
such as Chinese in mainland China. A recent cross-sec-
tional study of patients with diabetes in China found
that the EQ-VAS score was associated with duration of
diabetes and microvascular complications but not with
BMI or macrovascular complications [14]. In spite of
limited generalizability, our study demonstrated the
necessity of cross-cultural validation of even simple
health-status measures such as the VAS.
In conclusion, compared to its English counterpart,
the EQ-VAS appears less sensitive to different health
status in Chinese-speaking patients with type 2 diabetes
in Singapore. Future studies using qualitative research
methods are needed to ascertain the underlying reasons.
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